Having your say
We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.
You can respond to a consultation by writing to the address in the consultation letter.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like withheld.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA.
3 May 2013 PHARMAC is seeking feedback on a proposal to widen access to ursodeoxycholic acid and amend the criteria for its funded use. Closed: Friday, 17 May 2013.
18 April 2013 PHARMAC seeks feedback on listing the following for use in hospitals: methoxyflurane for use in painful procedures; etoricoxib and celecoxib for perioperative use; and to widen access to meloxicam to include perioperative use, and gabapentin to include preoperative use. Closed: Friday, 3 May 2013.
18 April 2013 PHARMAC is seeking feedback on a proposal to list sugammadex (Bridion) in Part II of Section H of the Pharmaceutical Schedule. Closed: Friday, 3 May 2013.
12 April 2013 PHARMAC has entered into provisional agreements with AFT Pharmaceuticals Ltd and Alcon New Zealand Limited for a range of eye drops. Closed: Monday, 29 April 2013.
Proposal to widen access to adalimumab for juvenile idiopathic arthritis and for fistulising Crohn’s disease
12 April 2013 PHARMAC is seeking feedback on a proposal to widen access to adalimumab (Humira and HumiraPen) to include juvenile idiopathic arthritis and fistulising Crohns disease, and to list a 20 mg strength of Humira, from 1 July 2013. Closed: Monday, 29 April 2013.
12 April 2013 PHARMAC is proposing to fund pegfilgrastim (Neulastim) for the prevention of neutropenia in patients undergoing cancer chemotherapy, and tocilizumab (Actemra) for systemic juvenile idiopathic arthritis. Closed: Monday, 29 April 2013.
4 April 2013 UPDATED: PHARMAC is seeking feedback on a proposal to amend the restrictions applying to certain pharmaceuticals in the Infections - Agents for Systemic Use Group in Section B and Part II of Section H of the Pharmaceutical Schedule. Closed: Thursday, 18 April 2013.
26 March 2013 PHARMAC is seeking feedback on a proposal to fund the antiplatelet agent ticagrelor (Brilinta). Closed: Friday, 12 April 2013.
12 March 2013 Closed: 5 April 2013.
11 March 2013 Closed.
Last updated: 19 August 2016